S&P 500   3,125.91 (-3.10%)
DOW   27,045.23 (-3.27%)
QQQ   215.28 (-2.76%)
AAPL   289.42 (-2.94%)
FB   197.36 (-1.68%)
MSFT   168.22 (-1.56%)
AMZN   1,967.02 (-2.10%)
CGC   19.61 (-3.45%)
BABA   205.06 (-0.53%)
MU   51.98 (-5.51%)
GE   11.20 (-5.56%)
TSLA   798.32 (-4.25%)
AMD   47.36 (-3.58%)
T   37.38 (-1.76%)
ACB   1.49 (-3.86%)
F   7.24 (-4.36%)
NFLX   360.06 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.29 (-3.55%)
GILD   69.23 (-5.03%)
S&P 500   3,125.91 (-3.10%)
DOW   27,045.23 (-3.27%)
QQQ   215.28 (-2.76%)
AAPL   289.42 (-2.94%)
FB   197.36 (-1.68%)
MSFT   168.22 (-1.56%)
AMZN   1,967.02 (-2.10%)
CGC   19.61 (-3.45%)
BABA   205.06 (-0.53%)
MU   51.98 (-5.51%)
GE   11.20 (-5.56%)
TSLA   798.32 (-4.25%)
AMD   47.36 (-3.58%)
T   37.38 (-1.76%)
ACB   1.49 (-3.86%)
F   7.24 (-4.36%)
NFLX   360.06 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.29 (-3.55%)
GILD   69.23 (-5.03%)
S&P 500   3,125.91 (-3.10%)
DOW   27,045.23 (-3.27%)
QQQ   215.28 (-2.76%)
AAPL   289.42 (-2.94%)
FB   197.36 (-1.68%)
MSFT   168.22 (-1.56%)
AMZN   1,967.02 (-2.10%)
CGC   19.61 (-3.45%)
BABA   205.06 (-0.53%)
MU   51.98 (-5.51%)
GE   11.20 (-5.56%)
TSLA   798.32 (-4.25%)
AMD   47.36 (-3.58%)
T   37.38 (-1.76%)
ACB   1.49 (-3.86%)
F   7.24 (-4.36%)
NFLX   360.06 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.29 (-3.55%)
GILD   69.23 (-5.03%)
S&P 500   3,125.91 (-3.10%)
DOW   27,045.23 (-3.27%)
QQQ   215.28 (-2.76%)
AAPL   289.42 (-2.94%)
FB   197.36 (-1.68%)
MSFT   168.22 (-1.56%)
AMZN   1,967.02 (-2.10%)
CGC   19.61 (-3.45%)
BABA   205.06 (-0.53%)
MU   51.98 (-5.51%)
GE   11.20 (-5.56%)
TSLA   798.32 (-4.25%)
AMD   47.36 (-3.58%)
T   37.38 (-1.76%)
ACB   1.49 (-3.86%)
F   7.24 (-4.36%)
NFLX   360.06 (-2.34%)
BAC   31.08 (-5.04%)
DIS   128.29 (-3.55%)
GILD   69.23 (-5.03%)
Log in

NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, Forecast & News

$0.82
-0.02 (-2.37 %)
(As of 02/25/2020 02:46 PM ET)
Today's Range
$0.81
Now: $0.82
$0.90
50-Day Range
$0.79
MA: $1.04
$1.30
52-Week Range
$0.40
Now: $0.82
$1.59
Volume301,464 shs
Average Volume623,506 shs
Market Capitalization$25.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.84 per share

Profitability

Net Income$-15,560,000.00

Miscellaneous

Employees7
Market Cap$25.89 million
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.


Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Citius Pharmaceuticals shares reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

When is Citius Pharmaceuticals' next earnings date?

Citius Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Citius Pharmaceuticals.

What price target have analysts set for CTXR?

2 Wall Street analysts have issued 1 year price objectives for Citius Pharmaceuticals' shares. Their forecasts range from $4.00 to $7.00. On average, they expect Citius Pharmaceuticals' stock price to reach $5.50 in the next year. This suggests a possible upside of 568.9% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

What is the consensus analysts' recommendation for Citius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

Has Citius Pharmaceuticals been receiving favorable news coverage?

News headlines about CTXR stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Citius Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Citius Pharmaceuticals.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 988,000 shares, a decrease of 21.0% from the January 15th total of 1,250,000 shares. Based on an average daily volume of 504,000 shares, the short-interest ratio is presently 2.0 days. Currently, 6.6% of the shares of the company are short sold. View Citius Pharmaceuticals' Current Options Chain.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Progenics Pharmaceuticals (PGNX), Real Goods Solar (RGSE), SCYNEXIS (SCYX), Opko Health (OPK), Zynerba Pharmaceuticals (ZYNE), FuelCell Energy (FCEL), Canopy Growth (CGC), Cronos Group (CRON), Melinta Therapeutics (MLNT) and Onconova Therapeutics (ONTX).

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 74)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 72)
  • Mr. Jaime Bartushak, CFO, Chief Accounting Officer & Principal Financial Officer (Age 51)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 64)
  • Mr. Andrew Scott, VP of Corp. Devel.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $0.82.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $25.89 million. Citius Pharmaceuticals employs 7 workers across the globe.View Additional Information About Citius Pharmaceuticals.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is http://www.citiuspharma.com/.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel